NOVEL THERAPIES TO ENHANCE ANTI-TUMOUR IMMUNITY
Grant number: 1139626 | Funding period: 2018 - 2021
Immunotherapy is a new approach to treat cancer, and works by promoting the immune system to attack cancer. Immunotherapies, such as checkpoint blockade and adoptive T cell therapy, are proving to be very successful in certain human cancers. However, combining immunotherapy with drugs that cause cancer cell death may be more effective. This project will investigate the potential of combining immunotherapy with a novel anti-cancer drug, in order to develop more effective treatments for cancer.
Related publications (7)
NKG7 Enhances CD8 T Cell Synapse Efficiency to Limit Inflammation
Emily J Lelliott, Kelly M Ramsbottom, Mark R Dowling, Carolyn Shembrey, Tahereh Noori, Conor J Kearney, Jessica Michie, Ian A Parish, Margaret A Jordan, Alan G Baxter, Neil D Young, Amelia J Brennan, Jane Oliaro
Cytotoxic lymphocytes are essential for anti-tumor immunity, and for effective responses to cancer immunotherapy. Natural killer c..
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
Emily J Lelliott, Isabella Y Kong, Magnus Zethoven, Kelly M Ramsbottom, Luciano G Martelotto, Deborah Meyran, Joe Jiang Zhu, Matteo Costacurta, Laura Kirby, Jarrod J Sandow, Lydia Lim, Pilar M Dominguez, Izabela Todorovski, Nicole M Haynes, Paul A Beavis, Paul J Neeson, Edwin D Hawkins, Grant A McArthur, Ian A Parish, Ricky W Johnstone
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive brea..
HOIP limits anti-tumor immunity by protecting against combined TNF and IFN-gamma-induced apoptosis
Andrew J Freeman, Stephin J Vervoort, Jessica Michie, Kelly M Ramsbottom, John Silke, Conor J Kearney, Jane Oliaro
The success of cancer immunotherapy is limited to a subset of patients, highlighting the need to identify the processes by which t..
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
Emily J Lelliott, Grant A McArthur, Jane Oliaro, Karen E Sheppard
The recent advent of targeted and immune-based therapies has revolutionized the treatment of melanoma and transformed outcomes for..
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Emily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, Magnus Zethoven, Lydia Lim, Peter KH Lau, Amanda J Oliver, Luciano G Martelotto, Laura Kirby, Claire Martin, Riyaben P Patel, Alison Slater, Carleen Cullinane, Anthony T Papenfuss, Nicole M Haynes, Grant A McArthur, Jane Oliaro, Karen E Sheppard
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring..
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
Jessica Michie, Conor Kearney, Edwin D Hawkins, John Silke, Jane Oliaro
One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs..